{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:54:48Z","timestamp":1785700488537,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.yebeh.2026.111172","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:03:47Z","timestamp":1783199027000},"page":"111172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Brivaracetam as viable monotherapy option for focal and generalized epilepsy"],"prefix":"10.1016","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8521-5830","authenticated-orcid":false,"given":"Lena","family":"Bender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2382-0506","authenticated-orcid":false,"given":"Andreas","family":"Schulze-Bonhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2026.111172_b0005","unstructured":"Holtkamp M*, May TW* (*geteilte Erstautorenschaft), Berkenfeld R, Bien CG, Coban I, Knake S, et al. Erster epileptischer Anfall und Epilepsien im Erwachsenenalter, S2k-Leitlinie, 2023. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: www.dgn.org\/leitlinien."},{"key":"10.1016\/j.yebeh.2026.111172_b0010","doi-asserted-by":"crossref","unstructured":"French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Therapeutics and technology assessment subcommittee of the American academy of neurology; quality standards subcommittee of the American academy of neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American academy of neurology and the American Epilepsy Society. Neurology. 2004;62:1261\u20131273. doi: 10.1212\/01.wnl.0000123695.22623.32.","DOI":"10.1212\/01.WNL.0000123695.22623.32"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111172_b0015","first-page":"130","article-title":"Quality of life in seizure-free patients with epilepsy on monotherapy","volume":"14","author":"Auriel","year":"2009","journal-title":"EpilepsyBehav EB Januar"},{"issue":"12","key":"10.1016\/j.yebeh.2026.111172_b0020","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1212\/WNL.54.12.2245","article-title":"Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial","volume":"54","author":"Beydoun","year":"2000","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111172_b0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1528-1157.1997.tb01120.x","article-title":"Topiramate monotherapy for partial onset seizures","volume":"38","author":"Sachdeo","year":"1997","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111172_b0030","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.51.4.1018","article-title":"An active-control trial of lamotrigine monotherapy for partial seizures","volume":"51","author":"Gilliam","year":"1998","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.yebeh.2026.111172_b0035","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1474-4422(15)00229-X","article-title":"Is a separate monotherapy indication warranted for antiepileptic drugs?","volume":"14","author":"Mintzer","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2026.111172_b0040","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin Pharmacol Adv Appl"},{"key":"10.1016\/j.yebeh.2026.111172_b0045","doi-asserted-by":"crossref","unstructured":"Lattanzi S, Foschi N, Martellino C, Audenino D, Boero G, Bonanni P, u. a. Conversion to brivaracetam monotherapy in clinical practice: a retrospective study. Neurol Ther 2024;13(2):389\u201398.","DOI":"10.1007\/s40120-024-00580-2"},{"key":"10.1016\/j.yebeh.2026.111172_b0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","article-title":"Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: a monocenter retrospective outcome analysis","volume":"61","author":"Hirsch","year":"2018","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111172_b0055","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/epi4.13078","article-title":"BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice","volume":"9","author":"Villanueva","year":"2024","journal-title":"Epilepsia Open"},{"issue":"12","key":"10.1016\/j.yebeh.2026.111172_b0060","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111172_b0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2018.02.005","article-title":"Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: two double-blind, randomized, multicenter, historical control","volume":"141","author":"Arnold","year":"2018","journal-title":"Phase III studies Epilepsy Res"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2026.111172_b0070","first-page":"165","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"EpilepsyBehav"},{"issue":"5","key":"10.1016\/j.yebeh.2026.111172_b0075","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/epi.17573","article-title":"Should substitution monotherapy or combination therapy be used after failure of the first antiseizure medication?","volume":"64","author":"Hakeem","year":"2023","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111172_b0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1684\/j.1950-6945.2003.tb00001.x","article-title":"Rational conversion from antiepileptic polytherapy to monotherapy","volume":"5","author":"Baulac","year":"2003","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2026.111172_b0085","doi-asserted-by":"crossref","unstructured":"Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007;63(6):680\u20138. doi: 10.1111\/j.1365-2125.2006.02829.x. Epub 2007 Jan 12. PMID: 17223857; PMCID: PMC2000585.","DOI":"10.1111\/j.1365-2125.2006.02829.x"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111172_b0090","first-page":"1","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"54","author":"Ryvlin","year":"2013","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111172_b0095","first-page":"339","article-title":"Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories","volume":"47","author":"Vrijens","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.yebeh.2026.111172_b0100","doi-asserted-by":"crossref","unstructured":"Ben-menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure. 1. 2003;12(3):131\u20135.","DOI":"10.1016\/S1059-1311(02)00251-0"},{"key":"10.1016\/j.yebeh.2026.111172_b0105","unstructured":"Strzelczyk A, Margraf NG, Faber SC, Fulgeri N, Schulze-Bonhage A. Demographics and care of epilepsy in older adults in Germany. Seizure. 11. 2025;S1059-1311(25)00036-6."},{"key":"10.1016\/j.yebeh.2026.111172_b0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eplepsyres.2016.08.018","article-title":"Tolerability, safety and efficacy of brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies","volume":"127","author":"Brodie","year":"2016","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111172_b0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2026.111172_b0120","doi-asserted-by":"crossref","unstructured":"Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, et al., SANAD II collaborators. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016\/S0140-6736(21)00247-6. Erratum in: Lancet. 2021 May 15;397(10287):1808. doi: 10.1016\/S0140-6736(21)01012-6. PMID: 33838757; PMCID: PMC8047799.","DOI":"10.1016\/S0140-6736(21)01012-6"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111172_b0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"issue":"9566","key":"10.1016\/j.yebeh.2026.111172_b0130","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"SANAD Study group. the SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2026.111172_b0135","doi-asserted-by":"crossref","unstructured":"Ben-Menachem E, Dominguez J, Sz\u00e1sz J, Beller C, Howerton C, Jensen L, McClung C, Roebling R, Steiniger-Brach B. Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open-label trial. Epilepsia Open. 2021;6(3):618-623. doi: 10.1002\/epi4.12522. Epub 2021 Aug 2. PMID: 34265173; PMCID: PMC8408586.","DOI":"10.1002\/epi4.12522"},{"key":"10.1016\/j.yebeh.2026.111172_b0140","article-title":"Second antiseizure medication monotherapy in patients with adult-onset epilepsy: a register-based analysis","volume":"155","author":"Polychronidis","year":"2024","journal-title":"EpilepsyBehav"},{"key":"10.1016\/j.yebeh.2026.111172_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286419873518","article-title":"Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience","volume":"12","author":"Steinhoff","year":"2019","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:36:33Z","timestamp":1785699393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505026002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"alternative-id":["S1525505026002933"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111172","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brivaracetam as viable monotherapy option for focal and generalized epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111172"}}